Navigation Links
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
Date:8/10/2009

l need and we are pleased to be on the road to provide additional treatment options for patients."

About GEMS(TM)

Gene Expression Modulation by Small-molecules (GEMS(TM)) is PTC's novel and proprietary technology platform for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology target processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules. PTC has successfully employed the GEMS technology in drug discovery programs in oncology, infectious diseases, cardiovascular diseases, and neuromuscular disorders with corporate partners such as Celgene, Gilead, Pfizer, and Schering-Plough.

About Hepatitis C (HCV)

Hepatitis C is inflammation of the liver caused by the hepatitis C virus. Approximately 4 million people in the U.S. are infected with hepatitis C, according to the National Institutes of Health. Additionally, the World Health Organization estimates 170 million persons are chronically infected with HCV worldwide and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. At least 80% of patients with hepatitis C develop a chronic liver infection. It is the leading cause of liver failure requiring liver transplantation in both the United States and Europe. The Centers for Disease Control, or CDC, estimate that approximately 8,000 to 10,000 patients die annually in the United States from complications resulting from this infection. There are no available vaccines against HCV. The current standard of care for the treatment of HCV is a combination of two drugs, interferon and ribavirin. More than 50% of patients infected with the genotype 1 strain of HCV generally do not respond to this therapy. In addition, there are significant side effects to this therapy, which often result in dose reductions or prem
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
2. The Breast Cancer Therapeutics Market in Australia
3. Amicus Therapeutics Announces Second Quarter 2009 Financial Results
4. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
5. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
9. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
10. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
11. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
(Date:9/2/2015)... ... 2015 , ... Whitehouse Laboratories is excited to announce that ... upcoming educational seminar and training session on Extractable & Leachable testing. Featuring a ... Updates & Case Studies on the Latest Compliance Implications of USP and ICH ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... (+45.5% at Constant Forex) Substantial Increase in Sales ... a pioneer and key player in the development and,commercialization of molecular diagnostic tests for cancer, today ... 30 June 2007 30 June 2008 Variation Variation ... ...
... Helps ... Break Down Language Barrier -, WASHINGTON, Aug. 1 ... ally to help them,integrate into the English-speaking mainstream of global ... Peter M. Leitner, President of MaxWell USA, LLC, and Dr. ...
... Aug. 1 Iomai Corporation,(Nasdaq: IOMI ... the merger of,Iomai with a wholly-owned subsidiary ... outstanding shares entitled to vote at the ... percent of the,votes cast. The transaction remains ...
Cached Biology Technology:Confirmation of Strong Growth Over the First Half of 2008 2MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership 2
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/24/2015)... MOUNTAIN VIEW, Calif. , Aug. 24, 2015  Based ... & Sullivan recognizes DERMALOG with the 2015 African Biometrics Company ... manufacturer and has achieved substantial commercial success in ... Nigeria , where it has implemented one of ... equipped 23 banks as well as the Central Bank of ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... , April 23, 2010 , Carlos Moreira , Chairman and Founder ... address to a selected audience of over 500,entrepreneurs and members of the science ... week-end in Cambridge,Massachusetts . , , ... Carlos Moreira will debate some of these initiatives ...
... Molecular biologist Alan Ashworth, Ph.D., FRS, the director of ... Cancer Research in London will receive the David T. Workman ... $50,000 from the Samuel Waxman Cancer Research Foundation will support ... "I,m both surprised and delighted that the Waxman Foundation has ...
... been working for more than a decade to understand ... Now researchers have discovered that microRNA actually moves between ... ultimately determine the types of cells that grow and ... wide range of fields, including medical gene therapy and ...
Cached Biology News:WISeKey Announce New Services and Solutions for Latin America at MIT 2WISeKey Announce New Services and Solutions for Latin America at MIT 3Alan Ashworth to receive award for his breakthrough work in breast cancer 2Production of biofuels could benefit by controlling the types of cells that develop in plants 2
Eagle's Ham's amino acids; EHAA...
... provides quick and easy operation of a ... control. The software is fully secure ... CFR Part 11 regulations, and compatible with ... IRsolutions versatility enables use in high-level research ...
... random mutations to the gene supplied by a ... a vector of choice to obtain a library ... be set to a desired value within 1-20 ... Mutations can be restricted to a desired ...
... Tecans new Enzyme-Linked Immunosorbent Assay (ELISA) analyzer ... is a dedicated EVO platform for reliableELISA ... and incubation units operated by the new ... available in three sizes - 100, 150, ...
Biology Products: